Sono-Tek Receives $1.12 Million Order from Global Medical Diagnostics Company for High-Volume Coating Platform
Globenewswire· 2025-06-23 19:00
文章核心观点 Sono - Tek公司获医疗诊断测试行业长期客户112万美元订单,体现公司能力提升及战略推进,符合其为创新驱动行业提供高性能涂层平台的战略 [1][3][4] 订单情况 - 公司获医疗诊断测试行业长期客户112万美元订单 [1] - 客户为全球医疗诊断平台制造商,与公司合作近十年,此前部署超十台中号超声涂层系统,每台价格11 - 15万美元,新订单标志合作重大进展 [2] 订单意义 - 订单体现客户对公司能力的信心,展示公司引导客户从研发机器转向高平均售价大规模生产系统的战略 [3] - 新系统支持复杂自动化和减少人工干预,可实现先进诊断耗材的可扩展生产,预计明年在美国客户工厂交付安装 [3] 公司战略 - 订单符合公司为医疗设备、替代能源和微电子等创新驱动行业提供全集成、高性能涂层平台以满足高产量制造可扩展性和自动化需求的战略 [4] 公司概况 - 公司1975年成立,是超声涂层技术先驱,成立50年来从为研发和实验室市场提供解决方案发展为全球领先企业,为创新驱动行业提供可扩展、高性能制造平台 [5] - 公司系统能为医疗设备、微电子、替代能源和工业生产等先进应用实现薄膜沉积的均匀性、材料效率和过程控制 [5]
Magna Mining Announces Funding Award from the Critical Minerals Innovation Fund (CMIF)
Newsfile· 2025-06-23 19:00
Magna Mining Announces Funding Award from the Critical Minerals Innovation Fund (CMIF)June 23, 2025 7:00 AM EDT | Source: Magna Mining Inc.Sudbury, Ontario--(Newsfile Corp. - June 23, 2025) - Magna Mining Inc. (TSXV: NICU) (OTCQX: MGMNF) (FSE: 8YD) (the "Company" or "Magna") is pleased to announce that the Ontario government has awarded funding for up to C$500,000 for work on the Company's Crean Hill project. The award will be applied towards metallurgical work related to enhancing precious me ...
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Globenewswire· 2025-06-23 19:00
REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal fr ...
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Prnewswire· 2025-06-23 19:00
Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder valueCAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study ( ...
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
Globenewswire· 2025-06-23 19:00
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association’s (ADA) 85th Scientific ...
Manufactured Housing: The Ultimate 'Sleep Well At Night' REIT Sector
Seeking Alpha· 2025-06-23 19:00
Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.The first catalyst is AI, which is disrupting many businesses and will generate substantial wealth for those who embrace technology. In aBrad, along with HOYA Capital, lead the investing group iREIT®+HOYA Capital. The service covers REITs, BDCs, MLPs, Pre ...
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Globenewswire· 2025-06-23 19:00
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regu ...
OTC Markets Group Welcomes Torex Gold Resources Inc. to OTCQX
Globenewswire· 2025-06-23 19:00
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Torex Gold Resources Inc. (TSX: TXG; OTCQX: TORXF), an intermediate gold producer based in Canada, has qualified to trade on the OTCQX® Best Market. Torex Gold Resources Inc. upgraded to OTCQX from the Pink® market. Torex Gold Resources Inc. begins trading today on OTCQX under the symbol “TORXF.” U.S. investors can find current ...
Sono Group N.V.’s CEO Shareholder Update – June 2025
Globenewswire· 2025-06-23 19:00
From OEM Pilots to Production Line: Scaling Solar Power in Commercial TransportWest Palm Beach, FL, June 23, 2025 (GLOBE NEWSWIRE) -- The solar technology company Sono Group N.V. (OTCQB: SEVCF) (hereafter referred to as “Sono Group” or “Sono”, parent company to Sono Motors GmbH or “Sono Motors”) today issued a shareholder update from George O'Leary, Managing Director and Chief Executive Officer. Dear Shareholders, The past six months have been about one thing: getting it done. After years of engineering, pi ...
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Prnewswire· 2025-06-23 19:00
– Broad label inclusive of all ages and disease severities – – Launch to be initiated in Germany –WARREN, N.J., June 23, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU). The authorization includes a broad label inclusive of all ages and disease severities."The European approval of Sephience is a great step in our e ...